Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.84
Salarius Pharmaceuticals Inc Aktie (SLRX) Neueste Nachrichten
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
DCOY Stock Price and Chart — BOATS:DCOY - TradingView — Track All Markets
Can Salarius Pharmaceuticals Inc. stock hit analyst price targets2025 Stock Rankings & Risk Managed Investment Signals - ulpravda.ru
Profit Review: Is Salarius Pharmaceuticals Inc. stock overvalued by current metrics2025 Analyst Calls & Weekly Setup with High ROI Potential - ulpravda.ru
Total assets of Salarius Pharmaceuticals, Inc. – NASDAQ:DCOY - TradingView — Track All Markets
Salarius Pharmaceuticals, Inc. Balance Sheet – NASDAQ:DCOY - TradingView — Track All Markets
Is Salarius Pharmaceuticals Inc. (FP10) stock worth buying before Fed actionShare Buyback & Consistent Return Investment Signals - ulpravda.ru
Will Salarius Pharmaceuticals Inc. stock maintain growth storyPortfolio Performance Report & Safe Swing Trade Setup Alerts - ulpravda.ru
Is Salarius Pharmaceuticals Inc. stock overvalued by current metricsBond Market & Free Real-Time Volume Trigger Notifications - ulpravda.ru
Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikesJuly 2025 Patterns & AI Optimized Trade Strategies - ulpravda.ru
Stock Quote - StocksToTrade
Is Salarius Pharmaceuticals Inc. stock gaining market shareJuly 2025 Trends & Risk Managed Trade Strategies - ulpravda.ru
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - TipRanks
After tax other income/expense of Salarius Pharmaceuticals, Inc. – NASDAQ:DCOY - TradingView — Track All Markets
Salarius Pharmaceuticals, Inc. Statistics – NASDAQ:DCOY - TradingView — Track All Markets
Salarius Pharmaceuticals, Inc. Earnings and Revenue – NASDAQ:DCOY - TradingView — Track All Markets
Salarius Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:DCOY - TradingView — Track All Markets
Discontinued operations of Salarius Pharmaceuticals, Inc. – NASDAQ:DCOY - TradingView — Track All Markets
Salarius Pharmaceuticals, Inc. Financial Statements – NASDAQ:DCOY - TradingView — Track All Markets
Salarius Pharmaceuticals, Inc. Income Statement – NASDAQ:DCOY - TradingView — Track All Markets
Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN
Is Salarius Pharmaceuticals Inc. (FP10) stock a momentum leader2025 Technical Overview & Fast Exit and Entry Strategy Plans - ulpravda.ru
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Nigeria
Salarius shareholders back directors, executive pay and auditor - MSN
Salarius Pharmaceuticals, Inc. will Change its Ticker to DCOY from SLRX - MarketScreener
Salarius Pharmaceuticals, Inc. will Change its Name to Decoy Therapeutics Inc - MarketScreener
Salarius Pharmaceuticals changes name to Decoy Therapeutics - MarketScreener
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker - Investing.com
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics - MarketScreener
Biotech rebrands as Decoy Therapeutics to pursue next-gen antivirals - Stock Titan
Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency - MSN
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach - Investing.com Nigeria
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Salarius Pharmaceuticals and Decoy Therapeutics announce merger - MSN
Salarius Pharmaceuticals (NASDAQ:SLRX) Downgraded by Wall Street Zen to Sell - Defense World
Salarius Shareholders Back Directors, Executive Pay and Auditor - TipRanks
Salarius Pharmaceuticals Appeals Nasdaq Delisting After Bid Deficiency - TipRanks
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting By Investing.com - Investing.com South Africa
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
Hanish, director at Salarius, sells shares worth $17 - Investing.com
Salarius Pharmaceuticals (NASDAQ: SLRX) appeals Nasdaq delisting over $1.00 bid rule - Stock Titan
Wall Street Recap: Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targetsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - The Manila Times
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):